Salman Marwa Ibrahim, Al-Shammari Ahmed Majeed, Emran Mahfodha Abbas
Department of Biotechnology, College of Science, University of Baghdad, Baghdad, Iraq.
Department of Experimental Therapy, Iraqi Center for Cancer and Medical Genetic Research, Mustansiriyah University, Baghdad, Iraq.
Front Mol Biosci. 2022 Sep 12;9:754100. doi: 10.3389/fmolb.2022.754100. eCollection 2022.
Oncolytic virotherapy is one of the emerging biological therapeutics that needs a more efficient tumor model to overcome the two-dimensional (2D) monolayer tumor cell culture model's inability to maintain tissue-specific structure. This is to offer significant prognostic preclinical assessment findings. One of the best models that can mimic the model are the three-dimensional (3D) tumor-normal cell coculture systems, which can be employed in preclinical oncolytic virus therapeutics. Thus, we developed our 3D coculture system using two types of breast cancer cell lines showing different receptor statuses cocultured with adipose tissue-derived mesenchymal stem cells. The cells were cultured in a floater tissue culture plate to allow spheroids formation, and then the spheroids were collected and transferred to a scaffold spheroids dish. These 3D culture systems were used to evaluate oncolytic Newcastle disease virus AMHA1 strain infectivity and antitumor activity using a tracking system of the Newcastle disease virus (NDV) labeled with fluorescent PKH67 linker to follow the virus entry into target cells. This provides evidence that the NDV AMHA1 strain is an efficient oncolytic agent. The fluorescently detected virus particles showed high intensity in both coculture spheres. Strategies for chemically introducing fluorescent dyes into NDV particles extract quantitative information from the infected cancer models. In conclusion, the results indicate that the NDV AMHA1 strain efficiently replicates and induces an antitumor effect in cancer-normal 3D coculture systems, indicating efficient clinical outcomes.
溶瘤病毒疗法是一种新兴的生物疗法,它需要一个更有效的肿瘤模型来克服二维(2D)单层肿瘤细胞培养模型无法维持组织特异性结构的问题。这是为了提供重要的预后临床前评估结果。能够模拟该模型的最佳模型之一是三维(3D)肿瘤-正常细胞共培养系统,其可用于临床前溶瘤病毒治疗。因此,我们使用两种显示不同受体状态的乳腺癌细胞系与脂肪组织来源的间充质干细胞共培养,开发了我们的3D共培养系统。将细胞培养在漂浮组织培养板中以形成球体,然后收集球体并转移到支架球体培养皿中。这些3D培养系统用于评估溶瘤新城疫病毒AMHA1株的感染性和抗肿瘤活性,使用标记有荧光PKH67连接物的新城疫病毒(NDV)追踪系统来跟踪病毒进入靶细胞的过程。这提供了证据表明NDV AMHA1株是一种有效的溶瘤剂。荧光检测到的病毒颗粒在两个共培养球体中均显示高强度。将荧光染料化学引入NDV颗粒的策略可从感染的癌症模型中提取定量信息。总之,结果表明NDV AMHA1株在癌症-正常3D共培养系统中能有效复制并诱导抗肿瘤作用,预示着良好的临床效果。